MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer

International Journal of Molecular Sciences

Volumn 13, Issue 12, 2012, Pages 16053-16064

  Li, Jiarui ^a   Ping, Zhang ^a   Ning, Hui ^b  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cervical cancer; Cisplatin; HeLa; MiR 218

Indexed keywords

CISPLATIN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 218; PROTEIN KINASE B; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN218 MICRORNA, HUMAN; RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC REGULATION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; SIGNAL TRANSDUCTION; STABLE EXPRESSION; UTERINE CERVIX CANCER; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; UTERINE CERVICAL NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; RNA, NEOPLASM; UTERINE CERVICAL NEOPLASMS;

EID: 84871709212     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms131216053     Document Type: Article

References (34)

1. Shi, J.F.; Chen, J.F.; Canfell, K.; Feng, X.X.; Ma, J.F.; Zhang, Y.Z.; Zhao, F.H.; Li, R.; Ma, L.; Li, Z.F.; et al. Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: A micro-costing study. BMC Health Serv. Res. 2012, 12, 123.
2. Lea, J.S.; Sunaga, N.; Sato, M.; Kalahasti, G.; Miller, D.S.; Minna, J.D.; Muller, C.Y. Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells. Reprod. Sci. 2007, 14, 20-28.
3. Ji, J.; Zheng, P.S. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells. Gynecol. Oncol. 2010, 117, 103-108.
4. Noh, W.C.; Kim, Y.H.; Kim, M.S.; Koh, J.S.; Kim, H.A.; Moon, N.M.; Paik, N.S. Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res. Treat. 2008, 110, 477-483.
5. Marinov, M.; Ziogas, A.; Pardo, O.E.; Tan, L.T.; Dhillon, T.; Mauri, F.A.; Lane, H.A.; Lemoine, N.R.; Zangemeister-Wittke, U.; Seckl, M.J.; et al. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin. Cancer Res. 2009, 15, 1277-1287.
6. Babcock, J.T.; Quilliam, L.A. Rheb/mTOR activation and regulation in cancer: Novel treatment strategies beyond rapamycin. Curr. Drug Targets 2011, 12, 1223-1231.
7. Yanokura, M.; Banno, K.; Kobayashi, Y.; Kisu, I.; Ueki, A.; Ono, A.; Masuda, K.; Nomura, H.; Hirasawa, A.; Susumu, N.; et al. MicroRNA and endometrial cancer: Roles of small RNAs in human tumors and clinical applications (Review). Oncol. Lett. 2010, 1, 935-940.
8. Jiang, Y.W.; Chen, L.A. microRNAs as tumor inhibitors, oncogenes, biomarkers for drug efficacy and outcome predictors in lung cancer (review). Mol. Med. Report 2012, 5, 890-894.
9. Kelly, B.D.; Miller, N.; Healy, N.A.; Walsh, K.; Kerin, M.J. A review of expression profiling of circulating microRNAs in men with prostate cancer. BJU Int. 2012, doi:10.1111/ j.1464-410X.2012.11244.x.
10. Nair, V.S.; Maeda, L.S.; Ioannidis, J.P. Clinical outcome prediction by microRNAs in human cancer: A systematic review. J. Natl. Cancer Inst. 2012, 104, 528-540.
11. Lujambio, A.; Calin, G.A.; Villanueva, A.; Ropero, S.; Sanchez-Cespedes, M.; Blanco, D.; Montuenga, L.M.; Rossi, S.; Nicoloso, M.S.; Faller, W.J.; et al. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl. Acad. Sci. USA 2008, 105, 13556-13561.
12. Lages, E.; Ipas, H.; Guttin, A.; Nesr, H.; Berger, F.; Issartel, J.P. MicroRNAs: Molecular features and role in cancer. Front. Biosci. 2012, 17, 2508-2540.
13. Uesugi, A.; Kozaki, K.; Tsuruta, T.; Furuta, M.; Morita, K.; Imoto, I.; Omura, K.; Inazawa, J. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res. 2011, 71, 5765-5778.
14. Martinez, I.; Gardiner, A.S.; Board, K.F.; Monzon, F.A.; Edwards, R.P.; Khan, S.A. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 2008, 27, 2575-2582.
15. Zhou, X.; Chen, X.; Hu, L.; Han, S.; Qiang, F.; Wu, Y.; Pan, L.; Shen, H.; Li, Y.; Hu, Z. Polymorphisms involved in the miR-218-LAMB3 pathway and susceptibility of cervical cancer, a case-control study in Chinese women. Gynecol. Oncol. 2010, 117, 287-290.
16. Rostaing, L.; Kamar, N. mTOR inhibitor/proliferation signal inhibitors: Eentering or leaving the field? J. Nephrol. 2010, 23, 133-142.
17. Morgensztern, D.; McLeod, H.L. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005, 16, 797-803.
18. Guo, C.; Gasparian, A.V.; Zhuang, Z.; Bosykh, D.A.; Komar, A.A.; Gudkov, A.V.; Gurova, K.V. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways. Oncogene 2009, 28, 1151-1161.
19. Breuleux, M.; Klopfenstein, M.; Stephan, C.; Doughty, C.A.; Barys, L.; Maira, S.M.; Kwiatkowski, D.; Lane, H.A. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol. Cancer Ther. 2009, 8, 742-753.
20. Brewer, C.A.; Blessing, J.A.; Nagourney, R.A.; McMeekin, D.S.; Lele, S.; Zweizig, S.L. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group. Gynecol. Oncol. 2006, 100, 385-388.
21. Long, H.J., III; Monk, B.J.; Huang, H.Q.; Grendys, E.C., Jr.; McMeekin, D.S.; Sorosky, J.; Miller, D.S.; Eaton, L.A.; Fiorica, J.V. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. Gynecol. Oncol. 2006, 100, 537-543.
22. Anders, J.C.; Grigsby, P.W.; Singh, A.K. Cisplatin chemotherapy (without erythropoietin) and risk of life-threatening thromboembolic events in carcinoma of the uterine cervix: The tip of the iceberg? A review of the literature. Radiat. Oncol. 2006, 1, 14.
23. Coleman, R.E.; Clarke, J.M.; Slevin, M.L.; Sweetenham, J.; Williams, C.J.; Blake, P.; Calman, F.; Wiltshaw, E.; Harper, P.G. A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix. Cancer Chemother. Pharmacol. 1990, 27, 52-54.
24. Nagai, Y.; Toita, T.; Wakayama, A.; Nakamoto, T.; Ooyama, T.; Tokura, A.; Inamine, M.; Kudaka, W.; Murayama, S.; Aoki, Y. Concurrent chemoradiotherapy with paclitaxel and cisplatin for adenocarcinoma of the cervix. Anticancer Res. 2012, 32, 1475-1479.
25. Nakada, S.; Aoki, D.; Ohie, S.; Horiuchi, M.; Suzuki, N.; Kanasugi, M.; Susumu, N.; Udagawa, Y.; Nozawa, S. Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: Sensitivity to cisplatin and clinical response. Int. J. Gynecol. Cancer 2005, 15, 445-452.
26. Calabro, A.; Singletary, S.E.; Tucker, S.; Boddie, A.; Spitzer, G.; Cavaliere, R. In vitro thermo-chemosensitivity screening of spontaneous human tumors: Significant potentiation for cisplatin but not adriamycin. Int. J. Cancer 1989, 43, 385-390.
27. Peng, D.J.; Wang, J.; Zhou, J.Y.; Wu, G.S. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem. Biophys. Res. Commun. 2010, 394, 600-605.
28. Wangpaichitr, M.; Wu, C.; You, M.; Kuo, M.T.; Feun, L.; Lampidis, T.; Savaraj, N. Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur. J. Pharmacol. 2008, 591, 124-127.
29. Tie, J.; Pan, Y.; Zhao, L.; Wu, K.; Liu, J.; Sun, S.; Guo, X.; Wang, B.; Gang, Y.; Zhang, Y.; et al. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet. 2010, 6, e1000879.
30. Boeri, M.; Pastorino, U.; Sozzi, G. Role of MicroRNAs in Lung Cancer: MicroRNA Signatures in Cancer Prognosis. Cancer J. 2012, 18, 268-274.
31. Li, X.; Wang, Q.; Zheng, Y.; Lv, S.; Ning, S.; Sun, J.; Huang, T.; Zheng, Q.; Ren, H.; Xu, J.; et al. Prioritizing human cancer microRNAs based on genes' functional consistency between microRNA and cancer. Nucleic Acids Res. 2011, 39, e153.
32. Brenner, B.; Hoshen, M.B.; Purim, O.; David, M.B.; Ashkenazi, K.; Marshak, G.; Kundel, Y.; Brenner, R.; Morgenstern, S.; Halpern, M.; et al. MicroRNAs as a potential prognostic factor in gastric cancer. World J. Gastroenterol. 2011, 17, 3976-3985.
33. Borralho, P.M.; Kren, B.T.; Castro, R.E.; da Silva, I.B.; Steer, C.J.; Rodrigues, C.M. MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J. 2009, 276, 6689-6700.
34. Luo, J.; Deng, Z.L.; Luo, X.; Tang, N.; Song, W.X.; Chen, J.; Sharff, K.A.; Luu, H.H.; Haydon, R.C.; Kinzler, K.W.; et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat. Protocols 2007, 2, 1236-1247.